Cambridge, United Kingdom
Endomag is a medical technology company focused on advancing global cancer care standards. The company's Sentimag® probe, Magseed® marker, and Magtrace® lymphatic mapping agent are widely utilized by top physicians and cancer centers worldwide. Founded in 2007 as a spin-out from the University of Houston and the University College London (UCL), Endomag operates from its headquarters in Cambridge, United Kingdom. The company's mission is to empower women with breast cancer to avoid unnecessary surgery and achieve improved outcomes when it is required. With a commitment to precision and minimally invasive care, Endomag has positively impacted thousands of women globally.
Notably, Endomag secured a significant £15.00M Series D investment on 30 November 2020, with Molten Ventures and Sussex Place Ventures being the key investors. The company operates within the Health Care, Information Technology, and Medical Devices industries, positioning itself at the forefront of innovative healthcare technologies.
